BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: A combination of imatinib with 5-aza-deoxycytidine, a demethylating agent, induced the expression of BIM and decreased cell proliferation and viability of CML cell lines (San Jose-Eneriz et al., 2009a).